JP4837233B2 - 新規なセファロタキサン、それらの製造方法、および通常の化学療法薬に耐性を有する癌、白血病、寄生生物の治療におけるおよび逆転剤としてのそれらの使用 - Google Patents

新規なセファロタキサン、それらの製造方法、および通常の化学療法薬に耐性を有する癌、白血病、寄生生物の治療におけるおよび逆転剤としてのそれらの使用 Download PDF

Info

Publication number
JP4837233B2
JP4837233B2 JP2002536285A JP2002536285A JP4837233B2 JP 4837233 B2 JP4837233 B2 JP 4837233B2 JP 2002536285 A JP2002536285 A JP 2002536285A JP 2002536285 A JP2002536285 A JP 2002536285A JP 4837233 B2 JP4837233 B2 JP 4837233B2
Authority
JP
Japan
Prior art keywords
alkyl
dichloromethane
mmol
och
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002536285A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004511560A (ja
JP2004511560A5 (enExample
Inventor
ジャン‐ピエール、ロバン
ロベール、ダル
フレディ、ドルイ
ジャン‐ピエール、マリ
ニナ、ラドセビック
ジュリ、ロバン
カリヌ、スショ
パトリシア、バタイユ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ChemGenex Pharmaceuticals Pty Ltd
Original Assignee
ChemGenex Pharmaceuticals Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ChemGenex Pharmaceuticals Pty Ltd filed Critical ChemGenex Pharmaceuticals Pty Ltd
Publication of JP2004511560A publication Critical patent/JP2004511560A/ja
Publication of JP2004511560A5 publication Critical patent/JP2004511560A5/ja
Application granted granted Critical
Publication of JP4837233B2 publication Critical patent/JP4837233B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2002536285A 2000-10-17 2000-10-17 新規なセファロタキサン、それらの製造方法、および通常の化学療法薬に耐性を有する癌、白血病、寄生生物の治療におけるおよび逆転剤としてのそれらの使用 Expired - Fee Related JP4837233B2 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2000/001593 WO2002032904A1 (en) 2000-10-17 2000-10-17 New cephalotaxanes, their method of preparation and their use in treatment of cancers, leukemias, parasites including thus resistant to usual chemotherapeutic agents and as reversal agents

Publications (3)

Publication Number Publication Date
JP2004511560A JP2004511560A (ja) 2004-04-15
JP2004511560A5 JP2004511560A5 (enExample) 2005-04-14
JP4837233B2 true JP4837233B2 (ja) 2011-12-14

Family

ID=11003995

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002536285A Expired - Fee Related JP4837233B2 (ja) 2000-10-17 2000-10-17 新規なセファロタキサン、それらの製造方法、および通常の化学療法薬に耐性を有する癌、白血病、寄生生物の治療におけるおよび逆転剤としてのそれらの使用

Country Status (12)

Country Link
US (1) US6579869B1 (enExample)
EP (1) EP1328527B1 (enExample)
JP (1) JP4837233B2 (enExample)
CN (1) CN1303084C (enExample)
AT (1) ATE319714T1 (enExample)
AU (1) AU7940500A (enExample)
CA (1) CA2426103A1 (enExample)
DE (1) DE60026557T2 (enExample)
DK (1) DK1328527T3 (enExample)
ES (1) ES2258024T3 (enExample)
PT (1) PT1328527E (enExample)
WO (1) WO2002032904A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7285546B2 (en) * 2000-10-17 2007-10-23 Stragen Pharma S.A. Cephalotaxanes, their method of preparation and their use in treatment of cancers, leukemias, parasites including those resistant to usual chemotherapeutic agents and as reversal agents
US20020128258A1 (en) * 2001-03-09 2002-09-12 Jean-Pierre Robin Therapeutical method involving subcutaneous administration of drugs containing cephalotaxine derivatives
WO2004009092A1 (en) 2002-07-17 2004-01-29 Chemgenex Pharmaceuticals Limited Formulations and methods of administration of cephalotaxines, including homoharringtonine
US7642252B2 (en) 2002-07-22 2010-01-05 Chemgenex Pharmaceuticals, Inc. Angiogenesis inhibition by cephalotaxine alkaloids, derivatives, compositions and uses thereof
WO2009148654A2 (en) 2008-03-03 2009-12-10 Sloan-Kettering Institute For Cancer Research Cephalotaxus esters, methods of synthesis, and uses thereof
US20120022250A1 (en) * 2009-03-11 2012-01-26 Jean-Pierre Robin Process for preparing cephalotaxine esters
CN102304132B (zh) * 2011-07-12 2015-01-28 南开大学 高效高立体选择性半合成三尖杉酯类生物碱的方法
JP6068472B2 (ja) * 2011-08-18 2017-01-25 ハンジョウ ベンシェン ファーマシューティカル シーオー．， エルティーディー．Ｈａｎｇｚｈｏｕ Ｂｅｎｓｈｅｎｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． アミノ化ホモハリントニン誘導体、その調製方法及び使用
CN103687859B (zh) * 2011-08-18 2016-08-17 杭州本生药业有限公司 高三尖杉酯碱的胺化衍生物、及其制备方法和应用
CN102675327B (zh) * 2012-03-01 2014-12-10 南开大学 三尖杉酯碱类似物及制备方法和应用
CN104293855A (zh) * 2014-10-15 2015-01-21 中国计量学院 脐孢木霉菌转化株在提高木霉素产量中的应用
WO2016182850A1 (en) 2015-05-08 2016-11-17 Albany Molecular Research, Inc. Methods and intermediates for the preparation of omacetaxine and cephalotaxine derivatives thereof
CN106866690B (zh) * 2015-12-10 2019-10-11 南开大学 三尖杉酯类生物碱、其制备方法和用途
CN109111459B (zh) * 2017-06-22 2021-10-29 南华大学 含水杨酸三尖杉碱酯衍生物、制造方法及其用途
CN108378049A (zh) * 2018-05-02 2018-08-10 孙利嫚 一种含有粗榧生物碱和甲氧虫酰肼的农药组合物
CN119968374A (zh) * 2022-09-22 2025-05-09 南开大学 三尖杉酯碱类衍生物及其药物组合物、制备方法和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999048894A1 (en) * 1998-03-20 1999-09-30 Oncopharm Corporation Novel cephalotaxane derivatives and process for their preparation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999048894A1 (en) * 1998-03-20 1999-09-30 Oncopharm Corporation Novel cephalotaxane derivatives and process for their preparation

Also Published As

Publication number Publication date
PT1328527E (pt) 2006-06-30
HK1063183A1 (en) 2004-12-17
DK1328527T3 (da) 2006-07-17
CN1303084C (zh) 2007-03-07
CA2426103A1 (en) 2002-04-25
DE60026557T2 (de) 2006-12-28
ES2258024T3 (es) 2006-08-16
CN1474821A (zh) 2004-02-11
AU7940500A (en) 2002-04-29
US6579869B1 (en) 2003-06-17
JP2004511560A (ja) 2004-04-15
DE60026557D1 (de) 2006-05-04
EP1328527A1 (en) 2003-07-23
WO2002032904A1 (en) 2002-04-25
ATE319714T1 (de) 2006-03-15
EP1328527B1 (en) 2006-03-08

Similar Documents

Publication Publication Date Title
JP4837233B2 (ja) 新規なセファロタキサン、それらの製造方法、および通常の化学療法薬に耐性を有する癌、白血病、寄生生物の治療におけるおよび逆転剤としてのそれらの使用
CN117567478B (zh) 喜树碱类化合物及其制备方法和应用
CN103717571B (zh) 9-氨基甲基取代的四环素类化合物
WO1994011376A1 (en) Camptothecin analogues and methods of preparation thereof
CN115850291A (zh) 喜树碱衍生物及其用途
EP4265620A1 (en) Novel camptothecin derivative, composition containing same, and use thereof
JP2022529212A (ja) 経口送達されるベータ－ラクタマーゼ阻害剤の固体形態およびその使用
CN113880767A (zh) 一种免疫调节剂
TWI290046B (en) Phenanthroindolizidine alkaloids
JP2006504753A (ja) 抗癌剤および抗感染症薬としてのジヒドロアルテミシニンおよびジヒドロアルテミシテンの二量体
EP2112154A1 (en) Esters in position 20 of camptothecins
KR100330698B1 (ko) 멀티드럭내성조절자로서의융합된이미다졸유도체
JP5620046B2 (ja) テモゾロマイドエステルよりなる医薬組成物
US7285546B2 (en) Cephalotaxanes, their method of preparation and their use in treatment of cancers, leukemias, parasites including those resistant to usual chemotherapeutic agents and as reversal agents
Tsuda et al. Purealidins EG, new bromotyrosine alkaloids from the Okinawan marine sponge Psammaplysilla purea
KR20250150138A (ko) 화합물의 염 및 이의 결정형, 제조 방법 및 용도
JP4305909B2 (ja) 六環式化合物
EP3937917B1 (en) Analogues and derivatives of cephalotaxine and methods for making and using the compounds
JP2008503582A (ja) 望ましい化学的官能基を有する抗がん及び抗原虫ジヒドロアーテミシニン及びジヒドロアーテミシテンダイマー
EP2474550A1 (en) Derivatives of Englerin for the treatment of cancer
CN111943914B (zh) 一种具有抗炎活性的化合物及其应用
CN120441439A (zh) 苯酞开环衍生物及其制备方法和用途
CN118184675A (zh) 野艾蒿内酯i衍生物及其药物组合物和其制备方法与应用
JP2000229977A (ja) トリデカノリド誘導体及び抗癌剤
WO2025087401A1 (zh) 稠环化合物及其制备方法和用途

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20040611

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20040611

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070510

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20091222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101001

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101222

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110131

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110228

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110902

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110928

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20141007

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees